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Mutations in HPSE2 Cause Urofacial Syndrome
Sarah B. Daly,1 Jill E. Urquhart,1 Emma Hilton,1 Edward A. McKenzie,2 Richard A. Kammerer,3
Malcolm Lewis,4 Bronwyn Kerr,1 Helen Stuart,1 Dian Donnai,1 David A. Long,5 Berk Burgu,6
Ozgu Aydogdu,6 Murat Derbent,7 Sixto Garcia-Minaur,8 Willie Reardon,9 Blanca Gener,10 Stavit Shalev,11
Rupert Smith,12 Adrian S. Woolf,4 Graeme C. Black,1 and William G. Newman1,*
Urinary voiding dysfunction in childhood, manifesting as incontinence, dysuria, and urinary frequency, is a common condition.
Urofacial syndrome (UFS) is a rare autosomal recessive disease characterized by facial grimacing when attempting to smile and failure
of the urinary bladder to void completely despite a lack of anatomical bladder outﬂow obstruction or overt neurological damage.
UFS individuals often have reﬂux of infected urine from the bladder to the upper renal tract, with a risk of kidney damage and renal
failure. Whole-genome SNP mapping in one affected individual deﬁned an autozygous region of 16 Mb on chromosome 10q23-q24,
withinwhich a 10 kb deletion encompassing exons 8 and 9 ofHPSE2was identiﬁed. Homozygous exonic deletions, nonsensemutations,
and frameshift mutations in ﬁve further unrelated families conﬁrmedHPSE2 as the causative gene for UFS. Mutations were not identiﬁed
in four additional UFS patients, indicating genetic heterogeneity. We show thatHPSE2 is expressed in the fetal and adult central nervous
system, where it might be implicated in controlling facial expression and urinary voiding, and also in bladder smoothmuscle, consistent
with a role in renal tract morphology and function. Our ﬁndings have broader implications for understanding the genetic basis of lower
renal tract malformations and voiding dysfunction.Dysfunctional urinary voiding manifests variously as
incontinence, dysuria, and urinary frequency. It can be
accompanied by a failure to coordinate relaxation of the
sphincter mechanism with bladder smooth muscle wall
(detrusor) contraction, without overt neurological or ana-
tomical explanation. It is common, affecting up to 15%
of children at 6 years of age.1 Unrecognized and untreated,
it can occasionally lead to kidney damage associated with
impaired ﬂow of urine from the upper renal tract into
the bladder and/or vesico-ureteric reﬂux (VUR) of infected
urine. The pathogenesis of dysfunctional urinary voiding
is unclear and may be informed by understanding the
basis of urofacial (Ochoa) syndrome (UFS [MIM 236730]),
a rare autosomal recessive disease characterized by a severe
and early-onset form of dysfunctional urinary voiding.2
Affected individuals usually present prenatally or in early
childhood with grossly distorted renal tracts, comprising
dysmorphic bladders and dilatation of the ureter and renal
pelvis. They are at high risk of VUR, with ascending bacte-
rial infection leading to kidney damage, hypertension, and
renal failure. A third of UFS children experience constipa-
tion or fecal soiling, suggesting that the pathophysiology
of the syndrome encompasses a broader functional impair-
ment of elimination.3 Affected individuals also have a char-
acteristic facial grimace when trying to smile, which both
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Previous homozygosity and linkage mapping studies
in consanguineous families of Columbian, American-Irish,
Spanish, and French extraction were undertaken with
microsatellite markers.4,5 These studies identiﬁed and
then ﬁne-mapped a locus to a 220 kb region of chromo-
some 10q23-q24 that was proposed to contain the causa-
tive gene.4,5 The region contained two genes, ACDP1
(MIM 607802) and GOT1 (MIM 138180), but subsequent
sequence analyses failed to identify pathogenic mutations
in any of the affected individuals.
Here we demonstrate that biallelic mutations in the
HPSE2 gene on chromosome 10q23-q24 are responsible
for some cases of UFS. Furthermore, we demonstrate that
the gene is normally expressed in both the central nervous
system and the bladder.
Family 1 (Figure 1) is a consanguineous British Pakistani
family with three siblings affected with UFS. The parents
are unaffected ﬁrst cousins. The proband (IV-4) presented
when 2 years old with acute renal failure and urinary
sepsis. He was found to have a hypercontractile bladder,
bilateral VUR, and hydronephrotic scarred kidneys. He
underwent a surgical ileal loop urinary diversion proce-
dure. When assessed at age 11, his glomerular ﬁltration
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Figure 1. Identification of Intragenic Deletion in HPSE2 in an Affected UFS Patient
(A) The pedigree of family 1 indicates the individuals who were screened by PCR for a deletion breakpoint, indicated by *. Filled-in
symbols represent affected individuals, and symbols containing a dot indicate heterozygote. SNP6.0 array performed on IV:4 is indicated
by an arrow.
(B) Photograph of affected siblings demonstrating characteristic grimace upon smiling.
(C) SNP6.0 array copy number analysis illustrating 11 probe deletions in HPSE2. Log2ratio, copy number state (CNState), and red bar all
indicate the deleted region, and an ideogram of chromosome 10 with the position of the deletion is indicated by a red triangle.was at the lower end of the normal range, and he
had modest proteinuria, a marker of kidney damage.
He required pharmacological treatment for hypertension.
When his sister (IV-3) was age 6, she was found to have
dysfunctional voiding with a hypocontractile bladder
and VUR; surgery was not undertaken, and her kidney
function is normal. The index case’s younger brother
(IV-5) presented with renal pelvis dilatation on antenatal
ultrasound screening. Postnatal investigations showed
a low-capacity, trabeculated bladder with VUR, and he
underwent surgical urinary diversion. Assessed at the age
of 10 years, he had structurally abnormal kidneys, a GFR
at the lower end of the normal range, and modest pro-
teinuria, but he was normotensive. All three affected
siblings have the UFS characteristic grimace upon smiling
(Figure 1).
Ethical approval for this study was obtained from the
University of Manchester (06138) and NHS ethics commit-
tees (06/Q1406/52). Informed consent was obtained from
all participating subjects or, in the case of children, from
their parents. Affymetrix SNP6.0 array genotyping in
individual IV-4 via AutoSNPa6 analysis revealed a homozy-
gous region of 16.65 Mb (ﬂanked by rs17346680 and
rs10786808) that encompassed the critical interval previ-964 The American Journal of Human Genetics 86, 963–969, June 11,ously deﬁned on 10q23-q24.5 Copy number analysis via
the CN5 algorithm from Affymetrix deﬁned an intragenic
homozygous deletion of a maximum 11.25 kb (from
rs12240940 to rs658053) encompassing exons 8 and 9 in
HPSE2 that encodes heparanase 2 (Figure 1). HPSE2 is situ-
ated at 100,208,867100,985,609 bp (National Center for
Biotechnology Information [NCBI] build 36) and therefore
lies immediately centromeric to the previously identiﬁed
critical region.5 PCR analysis and DNA sequencing across
the breakpoint deﬁned a complex rearrangement encom-
passing a 10.81 kb deletion and a 23 bp insertion at the
breakpoints. The rearrangement is proposed to result in
an in-frame deletion of exons 8 and 9 (c.1099-4166_
1320þ840delins23, p.V367_P440del) and in a removal of
74 amino acids. The mutation segregated with the disorder
within the family, and the mutation was not present in
a panel of ethnically matched controls or in the Database
of Genomic Variation.
Mutation screening of HPSE2 led to the identiﬁcation of
mutations in ﬁve previously reported unrelated families
(Table 1; Figure 2) with UFS.7–9 Primers for ampliﬁcation
of exons and exon-intron boundaries of HPSE2 were de-
signed with Primer3Plus by using NCBI reference sequence
NM_021828.4 for exons 1 to 12 and NM_001166246.1 for2010
Table 1. Mutations in HPSE2 Identified in UFS Patients
Family Ethnicity
Nucleotide
Change Exons
Amino
Acid Change
1 Asian c.1099-4166_1320þ
840delins23
8, 9 p.V367_P440del
2 Turkish c.1414C>T 10 p.R472X
3 Turkish c.457C>T 3 p.R153X
4 Turkish c.57dupC 1 p.A20RfsX45
5 Spanish c.449-?_610þ? 3 p.D150_T203del
6 Irish c.1465_1466del 10 p.N489PfsX126
Nomenclature is based on NCBI reference sequence NM_021828.4.transcript variant 4 alternative exon 12 (exon12b) (see
Table S1 available online for primer sequences and PCR
conditions). A homozygous nonsense mutation in exon
10 (c.1414C>T, p.R472X) was identiﬁed in a 16-year-old
Turkish female with a history of dysfunctional voiding,Figure 2. Identification of HPSE2 Mutations in UFS Families
Pedigrees and genomic sequence chromatograms of families 2, 3, 4
10 (p.R472X) was identiﬁed; in family 3, a frameshift mutation a
1 (p.A20RfsX45) was identiﬁed; in family 4, a homozygous nonsen
a 2 bp deletion at the end of exon 10 resulting in a frameshift (p.N489
no ampliﬁcation of exon 3 in the affected individual. M represents the
sents the negative control. All individuals screened are indicated b
containing a dot indicate heterozygote.
The Amea dysmorphic, poorly emptying bladder, and hydroneph-
rosis (family 2).7
In family 3, ﬁve affected members of another Turkish
family all carried two copies of a frameshift mutation
because of a homozygous single base pair insertion of
a cytosine in exon 1 resulting in a premature stop codon
at position 64 (c.dup57, p.A20RfsX45).8 A homozygous
nonsense mutation in exon 3 (c.457C>T, p.R153X) was
identiﬁed in 18-month-old Turkish twin brothers affected
by UFS (family 4).8 Both had presented with urosepsis
and were found to have dysmorphic bladders.
An in-frame deletion of exon 3 (c.449-?_610þ?, p.D150_
T203del) removing 54 amino acids was identiﬁed in a
12-year-old Spanish boywho presented at the age of 3 years
with urosepsis and was found to have dysfunctional
and dysmorphic bladder and upper renal tract dilatation
(family 5).9 A homozygous 2 base pair deletion at the
end of exon 10 resulting in a frameshift (c.1465_1466del,
p.N489PfsX126) was determined in two Irish sisters with
UFS, with strikingly different presentations (family 6).9, and 6. In family 2, a homozygous nonsense mutation in exon
s a result of a homozygous single base pair insertion in exon
se mutation in exon 3 (p.R153X) was identiﬁed; and in family 6,
PfsX126) was identiﬁed. Pedigree of family 5 and agarose gel reveal
100 bp DNA ladder,þ represents the positive control, and – repre-
y *, ﬁlled-in symbols represent affected individuals, and symbols
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Figure 3. Protein Structure of Heparanase 2
Model of the predicted 50 kDa subunit of human heparanase 2
(residues 195–592) based on the crystal structure of the family
51 a-L-arabinofuranosidase13 (Protein Data Bank code 1PZ2).
The part of the structure that is encoded by exons 8 and 9 is shown
in marine blue. The N and C termini are indicated. This ﬁgure was
prepared with the program PyMOL (DeLano Scientiﬁc LLC).The ﬁrst sister (II-1) was diagnosed at age 3 with bilateral
upper tract dilatation and a nonfunctioning left kidney.
Her sister (II-3) experienced recurrent urinary tract
infections but was not diagnosed until her third decade.
The parents were both conﬁrmed as heterozygotes for
the mutation and were not knowingly related to each
other.
The mutations segregated with the disease phenotype in
all families and were not identiﬁed on polymorphism data-
bases or in panels of ethnically matched controls (93
Pakistani, 96 Turkish, and 96 European). Importantly, we
did not identify HPSE2 mutations in four additional fami-
lies, two published cases8 and two other families with UFS
that we have ascertained. Three of these additional UFS
families were consanguineous, and heterozygosity for
polymorphic variants at the HPSE2 locus suggests that
UFS does not map to this locus and is likely to be geneti-
cally heterogeneous. This contrasts with previous genetic
mapping reports that deﬁned a single UFS locus at
10q23-q24.5,10
The nonsense mutations identiﬁed in two families,
p.R153X and p.R472X, are likely to lead to nonsense-
mediated decay of the transcript and absent protein.
Likewise, the frameshift mutations p.A20RfsX45 and
p.N489PfsX126 are predicted to result in either nonsense-
mediated decay or in unfolded proteins that are readily
degraded.
Therefore, the effects of the in-frame whole exonic dele-
tions of exons 8 and 9 (family 1) and exon 3 (family 5) were
considered. The Phyre method for protein fold recognition
by using one- and three-dimensional sequence proﬁles
coupled with secondary structure and solvation potential
information was used to predict the functional conse-
quence of the exon 8 and 9 deletion (Figure 3).11 Residues
195–592 of the heparanase 2 sequence were aligned to the
family 51 a-L-arabinofuranosidase with ClustalW,12 and
the structural model was generated by using the SWISS-
MODEL automated modeling server,13 with the alignment
between heparanase 2 and the family 51 a-L-arabinofura-
nosidase sequences as an input and the crystal structure
of the family 51 a-L-arabinofuranosidase14 (Protein Data
Bank code 1PZ2) chain A as a template. This predicted
that the deletion most likely results in an unstructured
protein that will be degraded. Further, the deletion of these
two exons should remove part of the active site (the residue
corresponding to Glu343 in heparanase 1, which is poten-
tially equivalent to Glu380 in heparanase 2).
In contrast, the exon 3 deletion was not modeled
because this sequence corresponds to the linker sequence,
which is cleaved off in heparanase 1 to yield an active
enzyme. The heparanase 2 exon 3 deletion mutant could
potentially form a properly folded and active protein.
It is noteworthy that this sequence is missing in isoform
4 (HPSE2a), which lacks exons 3 and 4.
A human multiple-tissue RNA dot blot (RNA Masterblot;
CLONTECH) hybridized with a full-length 32P-labeled
HPSE2b probe showed widespread HPSE2 expression in966 The American Journal of Human Genetics 86, 963–969, June 11,the adult central nervous system, including the spinal
cord, caudate nucleus, thalamus, substantia nigra, medulla
oblongata, putamen, and pons (Figure S1).
Furthermore, as assessed by RT-PCR of a human embry-
onic brain panel (MRC Newcastle Brain Tissue Resource)
from Carnegie stage 16 (week 6) and stage 21 (week 8)
human embryos, HPSE2 was expressed in the developing
forebrain, telencephalon, diencephalon, midbrain, hind-
brain, and spinal cord (Figure 4). Dot-blot analysis also
showed prominent HPSE2 expression in the adult uri-
nary bladder, and in situ hybridization, as previously
described,15 demonstrated that transcripts localized within
tissue sections to longitudinal and circular layers of detru-
sor muscle (Figure 4). On dot blots, it was apparent that
HPSE2 was also expressed in the adult fore-, mid-, and
lower gut and in both the adult and fetal kidney. As
assessed by RT-PCR of wild-type mouse bladder, brain,
kidney, and ureter,16 Hpse2 expression is widespread,
with all organs positive at E15 and in the adult samples
(Figure 4). In contrast, for Hpse1 at E15, the bladder,
kidney, and ureter are positive, with no expression in the
brain. In the adult samples, however, Hpse1 is also
expressed in the bladder, but there is no expression in
the brain; in addition, the kidney expression is positive,
but very weak, and the ureter is negative.
The HPSE2 transcript comprises 12 exons and encodes
a 592 amino acid polypeptide, heparanase 2 (previously
HPA2). Four potential isoforms of HPSE2 have been identi-
ﬁed, as a consequence of differential splicing.17 The four
different mRNAs encode putative proteins of 480, 534,
538, and 592 amino acids and result from differential2010
Figure 4. Expression of HPSE2 in Human and Murine Tissues
(A) RT-PCR demonstrating expression of HPSE2 in embryonic
brain tissue at Carnegie stages 16 and 21.
(B) Direct in situ RT-PCR detection of HPSE2 mRNA expression
human bladder tissue. Strong brown staining demonstrates
expression in longitudinal smooth muscle tissue.
(C) RT-PCR demonstrating expression of Hpse2 in E15 and adult
mouse bladder, brain, kidney, and ureter. Hpse1 expression at
E15 in the murine bladder, kidney, and ureter are positive, with
no expression in the brain. In adult mouse tissue, Hpse1 is
expressed in the bladder, but not in the brain. Hpse1 expression
in the adult kidney is positive, but very weak, and the ureter is
negative.splicing of exons 3 and 4. Because we identiﬁed a whole
exon pathogenic deletion of exon 3 in a family with UFS,
this suggests that the isoforms containing exon 3 are
critical for HPSE2 function.17 We were unable to obtain
mRNA derived from these patients, which precluded an
examination of the effect at the transcript level. The 2 bp
deletion in family 6 predicted to create a frameshift
mutation disrupts a consensus heparin-binding motif
(NHHNHN) at the boundary of exons 10 and 11 in
HPSE2. This may therefore produce a mutated form of
the protein that is unable to bind to its glycosaminoglycan
substrate. Removal of this activity would be consistent
with a predicted null phenotype and consistent with
the other disease-associated nonsense and frameshift
mutations.
HPSE2 was identiﬁed through sequencing of expressed
sequence tags homologous to HPSE1 (MIM 604724).17The AmeHPSE1 encodes heparanase 1 (HPA1), an endoglycosidase
enzyme (the active form consisting of a heterodimer of
8 kDA and 50 kDa subunits) that is known to cleave hep-
aran sulfate glycosaminoglycans from proteoglycan core
proteins. Heparanase 1 and the 2c isoform share 45%
homology spanning both subunits, with higher patches
of homology or identity covering critical regions, includ-
ing small subunit domains and catalytic glutamic acid
residues. We are currently investigating the proposal that
the heparanase 2 isoforms also have carbohydrate process-
ing activity and so play a role in extracellular matrix
remodeling (E.A.M., unpublished data).
Because of the association with an abnormal facial
expression and voiding dysfunction in UFS, it has been
suggested that the gene or genes mutated in the syndrome
may have roles within the brain and/or brainstem in areas
that control both facial expression and also bladder and
bowel voiding; for example, the midbrain contains the
pontine micturition center and facial nerve nucleus.18
However, it could also be speculated that the renal tract
dysfunction is caused by lesions in neurons within or
near the bladder and/or that the renal tract dysmorphol-
ogy could be caused by failure to form normally func-
tioning smooth muscle within the walls of bladder and
ureters. Indeed, neural networks are present even in devel-
oping bladders,19 whereas mutations of genes expressed
in urothelium or nascent smooth muscle can cause renal
tract malformations.20,21 When HPSE2 was ﬁrst described,
preliminary studies showed that transcripts were expressed
in adult human brain, bladder, uterus, small intestine,
and prostate.17 Our current data conﬁrm and extend these
observations, showing that the gene is widely expressed in
both the mature and nascent human brain and spinal
cord, consistent with the hypothesis that the UFS pheno-
type is generated by alteration of processes in the central
nervous system. On the other hand, the collective data
demonstrate that the gene is normally expressed within
the bladder itself, where transcripts are found in smooth
muscle cells. Our murine studies demonstrate that Hpse2
is also expressed in the developing bladder (as well as in
the adult organ). In addition, it is expressed in developing
ureters. These observations are consistent with a new
hypothesis, namely that heparanase 2 has key roles in
the structural and functional maturation of the lower renal
tract itself. Certainly, the observation that some affected
individuals present with markedly dysmorphic ureters as
fetuses (e.g., family 1) is consistent with a direct role for
HPSE2 in lower renal tract development. Furthermore,
that HPSE2 is expressed in both the adult and developing
kidney suggests that it may have intrinsic roles in this
organ, leading to the consideration that not all the renal
damage found in affected individuals is secondary to lower
tract dysfunction. In the mouse, it is also interesting that
although there is overlapping expression between Hpse1
and Hspe2 in the renal tract, only Hpse2 is expressed in
the developing and mature brain, indicating distinct roles
for the encoded proteins. However, it is unclear howrican Journal of Human Genetics 86, 963–969, June 11, 2010 967
absent HPSE2 expression in the central nervous system
and/or bladder causes UFS.We speculate that lack of hepar-
anase 2 affects the extracellular matrix composition and
hence growth factor signaling and muscle differentiation;
e.g., VEGF-A is normally expressed by the nascent bladder
and enhances detrusor growth,22 and this factor binds to,
and its activity may be modiﬁed by, matrix molecules
with heparan sulfate chains, which could be disrupted by
absent heparanase 2.
In summary, we have demonstrated that biallelic muta-
tions in HPSE2, predicted to abolish activity of heparanase
2, cause UFS in families from different ethnic groups.
Because of the variable phenotype of this condition, it is
likely that UFS is underrecognized as a cause of nonneuro-
pathic bladder. Further work to understand the biochem-
ical and genetic role of HPSE2 in normal urogenital devel-
opment will provide greater insight into urinary voiding
dysfunction and may be relevant in unraveling the
genetics of primary, nonsyndromic VUR, a common
familial condition,23 which can be associated with bladder
dysfunction and which, in the UK, causes up to 10% of
kidney failure, requiring treatment with renal transplanta-
tion and/or life-long dialysis.24Supplemental Data
Supplemental Data include one ﬁgure and one table and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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